Physical Activity Characteristics across GOLD Quadrants Depend on the Questionnaire Used by Demeyer, H et al.
RESEARCH ARTICLE
Physical Activity Characteristics across GOLD
Quadrants Depend on the Questionnaire
Used
Heleen Demeyer1,2, Elena Gimeno-Santos3,4,5, Roberto A. Rabinovich6, Miek Hornikx1,2,
Zafeiris Louvaris7, Willem I. de Boer8, Niklas Karlsson9, Corina de Jong10, Thys Van der
Molen11, Ioannis Vogiatzis7, Wim Janssens2, Judith Garcia-Aymerich3,4,5,
Thierry Troosters1,2*, Michael I. Polkey12, PROactive consortium¶
1 KU Leuven, Department of Rehabilitation Sciences, B-3000, Leuven, Belgium, 2 University Hospitals
Leuven, Department of Respiratory Diseases, B-3000, Leuven, Belgium, 3 Centre for Research in
Environmental Epidemiology (CREAL), Barcelona, Spain, 4 CIBER Epidemiologia y Salud Publica
(CIBERESP), Barcelona, Spain, 5 Universitat Pompeu Fabra (UPF), Barcelona, Spain, 6 ELEGI/Colt
laboratory, UoE/MRC Centre for Inflammation Research, The University of Edinburgh, Edinburgh, Scotland,
7 Dept of Critical Care Medicine, Pulmonary Rehabilitation Centre, Evangelismos Hospital, M. Simou and G.
P. Livanos Laboratories, National and Kapodistrian University of Athens, Thorax Foundation, Athens,
Greece, 8 Department of Pulmonology, Leiden University Medical Center, Leiden, Netherlands, 9 Astra
Zeneca, Mölndal, Sweden, 10 Department of General Practice, University Medical Center Groningen,
Groningen, Netherlands, 11 Department of Primary Care, University of Groningen, University Medical Centre
Groningen, Groningen, Netherlands, 12 NIHR Respiratory Biomedical Research Unit of the Royal Brompton
and Harefield NHS foundation Trust and Imperial College London, London, United Kingdom
¶ Membership of the PROactive consortium is listed in the Acknowledgments.
* thierry.troosters@med.kuleuven.be
Abstract
Background
The GOLDmultidimensional classification of COPD severity combines the exacerbation
risk with the symptom experience, for which 3 different questionnaires are permitted. This
study investigated differences in physical activity (PA) in the different GOLD quadrants and
patient’s distribution in relation to the questionnaire used.
Methods
136 COPD patients (58±21% FEV1 predicted, 34F/102M) completed COPD assessment
test (CAT), clinical COPD questionnaire (CCQ) and modified Medical Research Council
(mMRC) questionnaire. Exacerbation history, spirometry and 6MWD were collected. PA
was objectively measured for 2 periods of 1 week, 6 months apart, in 5 European centres;
to minimise seasonal and clinical variation the average of these two periods was used for
analysis.
Results
GOLD quadrants C+D had reduced PA compared with A+B (3824 [2976] vs. 5508 [4671]
steps.d-1, p<0.0001). The choice of questionnaire yielded different patient distributions
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clinical characteristics. PA was notably lower in patients with an mMRC score2 (3430
[2537] vs. 5443 [3776] steps.d-1, p <0.001) in both the low and high risk quadrants.
Conclusions
Using different questionnaires changes the patient distribution and results in different clini-
cal characteristics. Therefore, standardization of the questionnaire used for classification is
critical to allow comparison of different studies using this as an entry criterion.
Clinical Trial Registration
ClinicalTrials.gov NCT01388218
Introduction
Chronic Obstructive Pulmonary Disease (COPD) is the most common lung disease in the
world. In 2011, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy
proposed new recommendations for the assessment and management of patients with COPD,
using a multidimensional approach to classify patients into four quadrants. This classification
has the advantage of combining the risk of exacerbations, based on both lung function and
exacerbation history, with the symptoms experienced by patients [1]. It was hypothesised that
this quadrant classification would provide a better reflection of the complexity of COPD com-
pared to the uni-dimensional analysis of airflow limitation previously used for staging the
disease.
The stated goals of COPD assessment are to determine the severity of the disease, its impact
on the patient’s health status and the risk of future events, to ultimately guide therapy [2]. This
strategy provoked a release of new publications, the so called “GOLD rush” [3], mainly investi-
gating the classifications ability to predict future events, such as exacerbations, hospital admis-
sions and death. However two large combined datasets have shown that at least for the
prediction of death it offers no advantage over the preceding I-IV stage classification [4,5].
Physical activity (PA) has emerged as a strong–if not the strongest- predictor of both mor-
tality and risk of hospitalization due to a COPD exacerbation [6]. PA is of intuitive relevance to
quality of life and is decreased in patients with COPD compared to healthy people [7]. Using
the prior I-IV GOLD stage system it was possible to show a relationship, albeit not a strong
relationship, between PA and FEV1 [8,9]. A lower level of PA has previously been described
even in patients with GOLD stage I [10] or in newly diagnosed patients with COPD [11].
Increasing PA has become an additional non-pharmacological component of the recom-
mended treatment of patients with COPD, in addition to pulmonary rehabilitation.
In the 2013 GOLD recommendations, the COPD Assessment Test (CAT), the modified
Medical Research Council (mMRC) questionnaire or the Clinical COPD Questionnaire (CCQ)
can all be used for assessing symptoms. Previous research concluded that the quadrant distri-
bution of patients classified by the mMRC, CAT or CCQ score is not identical [12,13], but it is
not yet known whether the quadrant construct can differentiate patients based on their PA.
Therefore the aim of the present study is to investigate whether the new GOLD classification
captures differences in PA. For that purpose we posed two specific questions; first, what are the
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patients’ PA characteristics according to the different classifications and second, what is the
agreement between the different classifications?
Methods
Study population and design
As part of the PROactive project (www.proactivecopd.com, NCT01388218) 236 patients with
COPD [2] were followed during 1 year with repeated assessments in between. The present
non-interventional cross-sectional study is based on patients who completed the whole trial
and uses data captured during the interim and final visit, respectively 6 and 12 months after
the screening visit, that allowed prospective assessment of exacerbations. All patients signed a
written informed consent before starting any data collection. This study was approved by the
PROactive ethics and patient advisory boards and approved by the ethics committee at each
centre (Commissie medische ethiek van de universitaire ziekenhuizen KU Leuven; Medische
ethische toetsingscommissie universitair medisch centrum Groningen; Lothian ethics commit-
tee; South east Scotland research ethics committee; Scientific council of the general hospital for
chest diseases, Sotiria).
Patients were recruited from five European clinical centres [Leuven (Belgium), London and
Edinburgh (UK), Athens (Greece) and Groningen (The Netherlands)], participating in the
PROactive project. These centres were chosen to ensure geographical and cultural representa-
tion of a wide range of disease severity by comprising primary care, tertiary care and rehabilita-
tion centres. Patients had a smoking history of at least 10 pack years and were not suffering
from a respiratory disease other than COPD. Patients with orthopaedic or neurological com-
plaints which would limit PA and patients with cognitive impairment were excluded. More
detailed information has been described in detail elsewhere [14].
Clinical measurements
All patients underwent spirometry according to ERS-ATS standards [15] to confirm the diag-
nosis of COPD (screening visit) and to be used as part of the GOLD classification (final visit).
A 6-minute walk test (6MWD) was performed during the final visit in a 30m corridor, using
the best of 2 tests [16]. Results were expressed as a percentage of predicted normal values
[17,18].
Physical activity
PA was measured with the Dynaport Movemonitor (Mc Roberts BV, The Hague, The Nether-
lands) for two periods: 1 week preceding the interim visit and 1 week preceding the final visit.
The mean of both measurements (6 months apart) was used as an outcome measurement, with
the aim of lowering the influence of individual changes due to the weather and patient condi-
tion during 1 single measurement. Patients were asked to wear the monitor during waking
hours. The tri-axial accelerometer, worn at the height of the second lumbar vertebra has been
thoroughly validated in patients with COPD [19,20].
Valid days were defined as days with a wearing time of at least 8 hours, weekends were
excluded from the analysis, resulting in two periods of (maximum) five weekdays. Patients
with at least 2 valid days at both time points were included in the analysis. The measurement of
2 weekdays will provide the desirable intraclass correlation coefficient (0.80) for cross-sec-
tional analyses [21]. To account for potential misclassification in relation to decisions about
PA, all analyses were repeated using all patients with an overall (either of both measurements)
minimum of 2 days (week or weekend) of PA data (S1 File). The total amount of steps per day
Physical Activity across GOLDQuadrants
PLOS ONE | DOI:10.1371/journal.pone.0151255 March 14, 2016 3 / 14
and the proportion of patients showing inactivity (mean daily step value of<4580 steps [22])
were chosen as outcome measurements.
Questionnaires
The GOLD strategy recommends the use of either CAT, mMRC or the CCQ questionnaire for
the symptomatic assessment. The CAT measures the impact of COPD on a person’s health sta-
tus [23], a score10 is defined as having “high” symptoms in the GOLD strategy. The mMRC
assesses the disability due to breathlessness [24] where an mMRC grade 2 points indicates
having “high” symptoms in the current recommendation. The CCQ is developed to measure
symptom and functional status [25]. The cut-off for CCQ has to be finally determined in the
GOLD strategy but will be in the range 1–1.5. The present study considered a cut-off of1.5
[26].
Exacerbation history
Acute exacerbations were defined as ‘events in the natural course of the disease, characterized
by a change in the patients’ baseline dyspnea, cough and/or sputum, which is beyond normal
day-to-day variations, acute in onset and leading to a change in medication’[1]. Having two or
more exacerbations in the preceding year, or having at least one hospitalization for a COPD
exacerbation in the preceding year was defined as ‘at high risk’.
Definition of GOLD quadrants
The combined GOLD classification categorizes patients in 4 quadrants (A-D) taking into
account lung function, exacerbation history and symptoms [1]. The classification is in detail
described in Fig 1.
Statistics
Sample size was defined according to the main objective of the study [14]. We calculated
whether the available sample size provided enough statistical power to answer the research
question(s), concluding this sample sufficient (S1 File). Analyses were performed with the SAS
statistical package 9.3 (SAS institute, Cary, NC, USA) and GraphPad Prism 6.01 (GraphPad
Software, Inc, CA, USA). The normality of distribution was analyzed with the Shapiro-Wilk
test and visual inspection of the frequency distribution. Data are presented as mean±SD for
normally or median [interquartile range] for not normally distributed variables. Statistical sig-
nificance was set at p<0.05. The different research questions were answered based on the fol-
lowing analyses:
1. What are the patients’ characteristics according to the different classifications?Differences
in patient characteristics across the former stages and GOLD quadrants were analyzed
using a one way ANOVA (proc GLM) for continuous variables (chi square tests for categor-
ical variables) followed by a post hoc analysis (Tukey), if significant. Differences in daily
step count were analyzed using a Kruskal Walis test with post hoc pairwise comparison
(Mann-Whitney U), applying a Dunn’s correction for multiple testing. Because we hypothe-
sized a low number of patients in quadrant C, we pooled patients in quadrant A+C and B
+D to investigate the impact of symptoms on PA (Mann-Whitney U). Similarly, the differ-
ence in physical activity between patients in the upper quadrants (C+D) and stages (III+IV)
were compared to those of patients in the lower quadrants (A+B) and stages (I+II).
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2. What is the agreement between the different classifications using different definitions?
Agreement between the classifications (quadrants A to D), based on either CAT, mMRC or
CCQ questionnaire results, was investigated using a (pairwise) concordance analysis. A sim-
ple kappa–coefficient (κ) was calculated (κ>0.40 indicates moderate agreement; κ>0.60
indicates substantial agreement; κ>0.80 indicates almost perfect agreement[27]).
Results
General patient characteristics
A total of 191 patients with COPD completed the whole trial [14] and were considered for the
present study (S1 Fig). Twenty two patients had missing data of the GOLD stratifiers (mMRC,
CAT, CCQ or exacerbation history) and 33 additional patients had invalid PA data, resulting in a
total sample size of 136 patients (102 men, 34 women, 58±21% FEV1 predicted, 68±8 year) for the
present analysis, see Table 1. Patients included in the analysis did not differ from those excluded
based on insufficient valid PA data (Table A in S1 File). Patients wore the accelerometer for a total
of 8.7±1.3 valid (week)days, with a mean wearing time of 881±107 minutes. In total 75 patients
were allocated to C/D, of these 25 patients were categorized at high risk only based on their lung
function, 25 patients solely based on their exacerbation history (2 exacerbations /1admission)
and 25 based on both severe airflow limitation and the exacerbation history.
What are the patients’ characteristics according to the different
classifications?
The multidimensional classification as well as the spirometric GOLD stages could discriminate
for all GOLD stratifiers (FEV1%pred, mMRC, CAT, CCQ, exacerbation history), see Table 2
Fig 1. The newGOLD assessment. The classification combines the symptomatic assessment with the
patients’ spirometric classification and/or risk of exacerbations, resulting in 4 quadrants. To classify patients
first symptoms should be assessed with the mMRC, CAT or CCQ scale and investigator should determine if
the patient belongs to the left (less symptoms) or right (more symptoms) side of the box. Next the risk of
exacerbations should be assessed to determine if the patient belongs to the lower part of the box (low risk) or
the upper part of the box (higher risk). When assessing symptoms the mMRC, CAT or the CCQ scale can be
used; when assessing risk the highest risk according to GOLD grade or exacerbation history should be
chosen.
doi:10.1371/journal.pone.0151255.g001
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and Table B in S1 File. The different quadrants nor GOLD stages did differ in age, gender,
BMI, proportion of active smokers and wearing time of the activity monitor.
The former GOLD classification shows a gradual but substantially overlapping decline in
level of PA and accordingly a linear increase in proportion of inactive patients in the higher
stages. In all multidimensional classifications patients in the highest quadrants (D) are less
active and have a lower 6MWD compared to those in quadrant A (p<0.001). Using mMRC
shows a lower PA and decreased 6WMD in quadrant D vs C (p = 0.04 and p<0.001 respec-
tively) and B vs A (p = 0.02 and p<0.001 respectively), see Fig 2 and Table 2. The proportion of
active patients was the highest (2/3 of patients) in GOLD I and GOLD A quadrants, irrespec-
tive of the classification. Of all patients classified as inactive (n = 80), 16% was included in
GOLD stage IV whereas 49–54% (using mMRC, CAT or CCQ) are allocated in GOLD quad-
rant D. The sensitivity analyses using minimal PA restrictions (including weekend days)
showed comparable results (see S1 File, S2 Fig).
Patients classified as former GOLD stage III-IV (n = 50) show lower PA levels compared to
those in stages I-II (n = 86) (3698 [2865] vs. 5080 [4157] steps.day-1, p<0.001). Similarly,
patients in quadrants C-D (n = 75) present with a lower step count compared to those quad-
rants A-B (n = 61) (3824 [2976] vs. 5508 [4672] steps.day-1, p<0.001).
The impact of having symptoms on PA depends on the questionnaire used in the classifica-
tion (less vs. more symptoms; mMRC: 3430 [2537] vs. 5443 [3776] steps.day-1,p<0.001; CAT
3835 [3616] vs.5070 [3681] steps.day-1, p = 0.02; CCQ 3714 [3240] vs. 5278 [4253] steps.day-1,
p<0.001). PA was notably lower in patients with a higher mMRC score. Fig 3 depicts the
impact of using mMRC, CAT and CCQ categorisation on the PA level.
What is the agreement between the different classifications?
Using mMRC, CAT or CCQ questionnaire to define symptoms resulted in different classifica-
tions of patients (Table 3 and Fig 4) The agreement between the classification of patients, based
on mMRC and CAT questionnaire was moderate (κ = 0.57 [95% CI 0.47–0.67]). The agree-
ment between the classification based on CCQ questionnaire and respectively the classification
Table 1. Patient characteristics.
Variable Patient characteristics (n = 136)
Female/male* 34 (25) / 102 (75)
Age (y) 68 ± 8
BMI (kg.m-2) 27 ± 5
FEV1 (%pred) 58 ± 21
6MWD (m) 444 ± 129
CAT score 14 ± 8
CCQ score 1.8 ± 1.0
mMRC (0/1/2/3/4)* 19 (14) / 53 (39) / 36 (26) / 27 (20) / 1 (1)
Active smokers* 18 (13)
COPD exacerbations (n.y-1)& 1 (0–12)
Hospitalizations due to COPD exacerbation (n.y-1) & 0 (0–4)
Data are presented as mean ± SD
*data presented as n (%)
&data presented as median (min-max)
BMI missing in 2 patients, 6MWD missing in 6 patients
doi:10.1371/journal.pone.0151255.t001
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based on mMRC and CAT questionnaire was substantial (κ = 0.71 [95%CI 0.62–0.80] and κ =
0.72 [95%CI 0.63–0.80]).
Discussion
Our results show that patients identified by the multidimensional GOLD classification as being
at high risk also have severely decreased PA level. However, the data also show that the use of
Table 2. Patient characteristics across the different GOLD quadrants usingmMRC, CAT or CCQ score to define symptoms experience.
Variable Combined assessment (mMRC)
A (n = 46) B (n = 15) C (n = 26) D (n = 49) p- value
FEV1 (%pred) 74±15 66±17 55±18
A 42±18 AB <0.01
mMRC (score) 0.7±0.5 2.4±0.5A 0.9±0.3 B 2.5±0.5 AC <0.01
CAT (score) 10±5 17±8A 11±6 B 19±7 AC <0.01
CCQ (score) 1.1±0.7 2.1±0.9 A 1.4±0.8 B 2.5±0.8 AC <0.01
Exacerbations (n.y-1)& 0[0] 0[1] 2[1] AB 3[3]AB <0.01
Hospitalizations (n.y-1)& 0 0 0[0] AB 0[0]AB <0.01
6MWD (m) 523±98 349±96 A 498±100B 367±115 AC <0.01
6MWD (%pred) 83±15 55±12 A 79±14B 60±18 AC <0.01
Inactive patients (%)* 16 (35) 11(73) A 14 (54) 39 (80)AC <0.01
Variable Combined assessment (CAT)
A (n = 27) B (n = 34) C (n = 16) D (n = 59) p- value
FEV1 (%pred) 75±17 70±15 50±20
AB 46±18 AB <0.01
mMRC (score) 0.7±0.7 1.4±0.9 A 1.4±0.8 2.1±0.9 ABC <0.01
CAT (score) 6±2 16±5 A 6±3 B 19±7 ABC <0.01
CCQ (score) 0.8±0.6 1.8±0.7 A 1.1±0.6 B 2.4±0.9 ABC <0.01
Exacerbations (n.y-1)& 0[0] 0[1] 1[2] 2[3]AB <0.01
Hospitalizations (n.y-1)& 0 0 0[0] 0[0]AB <0.01
6MWD (m) 519±111 452±126 449±149 404±118A <0.01
6MWD (%pred) 83±18 71±7 72±20 65±18A <0.01
Inactive patients (%)* 9 (33) 18 (53) 12 (75) A 41 (69) A <0.01
Variable Combined assessment (CCQ)
A (n = 40) B (n = 21) C (n = 16) D (n = 59) p- value
FEV1 (%pred) 75±15 67±15 54±21
A 44±17AB <0.001
mMRC (score) 0.8±0.7 1.6±1.0A 1.0±0.7 2.2±0.8 ABC <0.001
CAT (score) 9±4 16±7 A 8±4B 19±7 AC <0.001
CCQ (score) 0.8±0.3 2.4±0.5 A 0.9±0.4 B 2.5±0.8 AC <0.001
Exacerbations (n.y-1)& 0[0.5] 0[1] 1[2] 2[3]AB <0.001
Hospitalizations (n.y-1)& 0[0] 0[0] 0[0] 0[0]AB <0.001
6MWD (m) 513±106 416±134 A 485±137 394±116 AC <0.001
6MWD (%pred) 81±16 65±18A 74±17 64±19AC 0.001
Inactive patients (%)* 15(38) 12(57) 10(63) 43(73)A 0.006
Data are presented as mean ± SD
* = data presented as n (%)
&data presented as median [IQR]
p-value results from a one-way ANOVA, chi square test(*) or Kruskal wallis test (&); Post hoc analyses, adjusted for multiple testing
Adifferent from A (B, C or D)
Bdifferent from B (C or D)
Cdifferent from C (D)
doi:10.1371/journal.pone.0151255.t002
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different questionnaires results in a different patient distribution with different clinical charac-
terization. Moreover, PA is notably lower in patients with a higher mMRC score, both in the
low and high risk quadrants. Importantly, independent of the questionnaire used, approxi-
mately 30% of patients in quadrant A (i.e. low risk, low symptoms) show inactivity and 27 out
of 80 (34%) inactive patients are classified in the low risk quadrants.
PA decreases with worse lung function [7,10]. In the multidimensional GOLD classification,
by adding the history of exacerbations, more patients are shifted to the higher risk categories
[5]. The very low PA seen in these upper quadrants, consistently related to the risk for an
exacerbation and mortality [6], confirms the ability of the GOLD classification to identify
severe patients, in need of maximal therapy. According to the GOLD guidelines, these patients
require a maximal non-pharmacological treatment strategy including pulmonary rehabilitation
and PA management [2].
COPD patients experience multiple symptoms, such as dyspnea, fatigue, anxiety and
depression, influencing physical and social functioning [28]. Dyspnea, the major cause of
Fig 2. Physical activity across different GOLD classifications.GOLD = Spirometric GOLD classification; mMRC = combined assessment using mMRC;
CAT = combined assessment using CAT; CCQ = combined assessment using CCQ; Significant differences (post hoc analysis) are indicated with a solid line.
doi:10.1371/journal.pone.0151255.g002
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disability in COPD, has already shown to be a better predictor of future mortality compared to
severity of lung function [29]. Previous research showed a 5 to 8 fold increase in risk of cardio-
vascular and cancer mortality in quadrants B and D compared to A and C [30] and the highest
prevalence of comorbidities and persistent inflammation was observed in patients in quadrant
B [31], using mMRC in the classification. These data are in line with the present results and
current literature showing an important link between physical (in)activity, important comor-
bidities [32] and related mortality [33]. Our data by showing a decreased physical activity in
patients with higher mMRC score, independent of the risk assessment, supports the idea that
mMRC is an important predictor of mortality [29], is mediated by a decreased PA in these
patients.
An important aim of the GOLD strategy is to guide treatment of COPD patients. In patients
at high risk, adding the symptom classification does not introduce significant changes to the
(maximal) treatment decisions. However, in patients at low risk (e.g. patients in primary care)
Fig 3. Physical activity across different mMRC, CAT and CCQ cut-offs.Upper panels present physical activity data, significant differences (post hoc
analysis) are indicated with a solid line; lower panels depict proportion of patients defined as sedentary (black bars). Dotted line present cut off used in the
GOLD classification; A/C and B/D indicate respectively quadrants A or C and B or D.
doi:10.1371/journal.pone.0151255.g003
Table 3. Frequency distribution of patients according to different GOLD classifications.
I (FEV180%) II(50%FEV1<80%) III (30%FEV1<50%) IV (FEV130%)
GOLD 19 (14%) 67 (49%) 35 (26%) 15 (11%)
A (Low R, Low S) B (Low R, High S) C (High R, low S) D (High R, High S)
mMRC 46 (34%) 15 (11%) 26 (19%) 49 (36%)
CCQ 40 (29%) 21 (15%) 16 (12%) 59 (43%)
CAT 27 (20%) 34 (25%) 16 (12%) 59 (43%)
GOLD = (former) spirometric GOLD classiﬁcation, mMRC = combined assessment using mMRC questionnaire, CAT = combined assessment using CAT
scores, CCQ = combined assessment using CCQ questionnaire; Low R = low severity on risk assessment; High R = high severity on risk assessment;
Low S = less symptoms; High S = more symptoms
doi:10.1371/journal.pone.0151255.t003
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classifying patients in quadrant A or B will change the recommended treatment choice (e.g.
starting rehabilitation) [2]. Our data suggest that the classification using mMRC would provide
a better discrimination for the need for this non-pharmacological therapy. The different ques-
tionnaires will result in different patient distributions, leading to different clinical characteris-
tics such as PA and 6MWD in the quadrants. Previous research showed the difference in
patient distribution [12,13], but none investigated the differences in clinical characteristics,
important for non-pharmacological treatment decisions. Although it could be argued that the
multidimensional classification was proposed for disease management and not for prognostic
purpose, interestingly, Casanova et al. showed the classification using mMRC was superior in
the ability to predict mortality than the CAT and CCQ (using a cut-off of 1.0)[34]. These data
could be related to our results showing the differences in PA across these classifications. Addi-
tionally, our data show the possible impact on non-pharmacological treatment decisions
according to the choice of questionnaire. Taking all this into account, our data clearly echo the
claim of Agusti, et al. that standardization of the choice of questionnaire to attribute the GOLD
strata is needed [35].
Previous research reporting on PA across the different quadrants are mainly based on
mMRC to classify patients and only measured PA at one time point. Moreira and colleagues
did not find any difference in objectively measured activity time between quadrants B to D nor
between the former stages [36], the latter is in contrast with available literature [10]. In line
with our results, lower levels of PA of patients in quadrant B and D were concluded in the
study of Boland,et al. [37], although the methodology of PA measurement was not specified.
PA data across GOLD quadrants using the St. George’s Respiratory Questionnaire (SGRQ) as a
surrogate for CAT showed the lowest PA level in patients in quadrant D. These authors
reported a higher PA level in patients in quadrant C compared to B (although significance was
not reported), in contrast with our results. This difference could, besides a difference in the
questionnaire used (SGRQ), be explained by the low number of patients in quadrant C (5% of
the sample) or the differences in PA monitoring properties and analysis [38].
A review by the GOLD scientific committee recommended studies comparing the specific
symptoms-evaluating tools [35]. To the best of our knowledge this is the first study investigat-
ing the differences between the combined GOLD classifications, using each one of the three
Fig 4. Patient distribution across the different GOLD classifications. The size of the squares represent the patient distribution relative to quadrant A.
mMRC = combined assessment using mMRC; CAT = combined assessment using CAT; CCQ = combined assessment using CCQ.
doi:10.1371/journal.pone.0151255.g004
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permitted questionnaires to evaluate symptom experience, in physical activity and exercise
capacity characteristics of patients. Based on our data we hypothesize a need for different thera-
peutic strategies in terms of non-pharmacological treatment of patients with COPD in the dif-
ferent GOLD quadrants, depending on the classification, particularly in the low risk quadrants.
Future research is needed to evaluate whether these treatment choices would yield different
benefits.
Physical activity was objectively measured using an accelerometer validated for use in
patients with COPD [19,20]; self-reported PA is known to relate poorly to objectively measured
data [39]. With the aim of decreasing variability, a valid physical activity measurement was
defined as having at least 2 weekdays of measurement on both time points [21]. Nevertheless
because physical activity has shown to be lower during weekends compared to weekdays [40],
we repeated the analyses including weekends (sensitivity analysis, see S1 File) to account for
potential misclassification in relation to decisions about PA, which resulted in similar conclu-
sions. We have chosen to use the number of steps as outcome measurement, known to be a
more sensitive outcome in this patients population compared to e.g. time in moderate physical
activity and lowered seasonal influence by combining 2 measurement periods [21]. Including
patients in different European centers, representing a wide range of severity and physical activ-
ity, improves the representation of the COPD population. When compared to 3 large cohorts
(ECLIPSE, Cocomics, COPDgene), using the mMRC in the classification [35], the present
study shows a very similar distribution (A 31%, B 17%, C 16%, D 37%).
Conclusions
The present study shows that patients identified by the multidimensional GOLD classification
as being at high risk also have severely decreased physical activity levels. Using different ques-
tionnaires in the classification changes both the patient distribution and results in different
clinical characteristics. We therefore believe that standardization of the questionnaire used for
GOLD classification is critical first to allow fair comparison of different studies using this as an
entry criterion and second to be used as base for treatment recommendations. Our data suggest
that the mMRC may be the most useful. Lastly we highlight that a significant minority of
patients in quadrant A have reduced PA emphasizing the importance of PA promotion even in
milder and apparently asymptomatic patients.
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